Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8039451 | ANACOR PHARMS INC | Boron-containing small molecules |
Jun, 2029
(5 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9682092 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Feb, 2027
(3 years from now) | |
US8501712 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Feb, 2027
(3 years from now) | |
US8501712 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Aug, 2027
(3 years from now) | |
US9682092 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Aug, 2027
(3 years from now) | |
US8039451 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Dec, 2029
(6 years from now) | |
US8168614 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Jan, 2030
(6 years from now) | |
US8168614 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Jul, 2030
(6 years from now) |
Eucrisa is owned by Anacor Pharms Inc.
Eucrisa contains Crisaborole.
Eucrisa has a total of 8 drug patents out of which 0 drug patents have expired.
Eucrisa was authorised for market use on 14 December, 2016.
Eucrisa is available in ointment;topical dosage forms.
Eucrisa can be used as method of treating mild to moderate atopic dermatitis..
The generics of Eucrisa are possible to be released after 20 July, 2030.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Mar 23, 2023 |
Pediatric Exclusivity (PED) | Sep 23, 2023 |
Drugs and Companies using CRISABOROLE ingredient
Market Authorisation Date: 14 December, 2016
Treatment: Method of treating mild to moderate atopic dermatitis.
Dosage: OINTMENT;TOPICAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic